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Induced pluripotent stem cells (iPSCs) with potential for 
therapeutic applications can be derived from somatic cells 
via ectopic expression of a set of limited and defined tran-
scription factors. However, due to risks of random inte-
gration of the reprogramming transgenes into the host 
genome, the low efficiency of the process, and the poten-
tial risk of virally induced tumorigenicity, alternative meth-
ods have been developed to generate pluripotent cells 
using nonintegrating systems, albeit with limited success. 
Here, we show that c-KIT+ human first-trimester amni-
otic fluid stem cells (AFSCs) can be fully reprogrammed to 
pluripotency without ectopic factors, by culture on Matri-
gel in human embryonic stem cell (hESC) medium sup-
plemented with the histone deacetylase inhibitor (HDACi) 
valproic acid (VPA). The cells share 82% transcriptome 
identity with hESCs and are capable of forming embryoid 
bodies (EBs) in vitro and teratomas in vivo. After long-term 
expansion, they maintain genetic stability, protein level 
expression of key pluripotency factors, high cell-division 
kinetics, telomerase activity, repression of X-inactivation, 
and capacity to differentiate into lineages of the three 
germ layers, such as definitive endoderm, hepatocytes, 
bone, fat, cartilage, neurons, and oligodendrocytes. We 
conclude that AFSC can be utilized for cell banking of 
patient-specific pluripotent cells for potential applications 
in allogeneic cellular replacement therapies, pharmaceuti-
cal screening, and disease modeling.
Received 28 February 2012; accepted 21 May 2012; advance online 
publication 3 July 2012. doi:10.1038/mt.2012.117
IntroductIon
Initially derived from fibroblasts by ectopic overexpression of 
OCT4, SOX2, c-MYC, and KLF4 from retroviral vectors,1 induced 
pluripotent stem cell (iPSC) technology has raised the possibility 
of generating an unlimited source of disease- and patient-specific 
PSCs with potential applications in regenerative medicine and in 
disease pathology investigation. Although clinical trials are pres-
ently underway using iPSC technology, there are still a number 
of hurdles to overcome, including the risks associated with the 
random integration of the reprogramming transgenes into the 
host genome (virally induced tumorigenicity), the low efficiency 
of the process, and the stability of the pluripotent phenotype.2 
Alternative methods have been developed to generate integra-
tion-free iPSC such as adenovirus,3 Sendai virus,4 episomal DNA 
plasmid,5 and minicircle DNA vectors.6 Other approaches include 
the use of piggyBac transposons7 and direct delivery of synthetic 
RNA8 or protein.9 However, non-integration methods are either 
inefficient or technically challenging, and although progress has 
been made to increase the efficiency of episomal plasmid vectors 
using p53 suppression,10 this may lead to genomic instability. In 
addition, the choice of donor cell source affects both the stabil-
ity and efficiency of reprogramming in relation to the tissue of 
origin,11 epigenetic memory, donor’s age, and characteristics of the 
parental cell population.12
Recent findings suggest that endogenous expression of key 
genes may favor the reprogramming process of cells. For example, 
neural stem cells, which endogenously express Sox2 and c-Myc, 
could be reprogrammed through ectopic expression of Oct4 and 
klf413 or by Oct4 alone.14 In addition, germ line cells, which endog-
enously express Oct4, could acquire pluripotency without addi-
tion of exogenous transcription factors15 and epiblast stem cells 
could revert to human embryonic stem cell (hESC)-like pluripo-
tency by small molecules supplementation.12
Amniotic fluid stem cells (AFSCs) are free of ethical constrains, 
can be readily isolated during amniocentesis without injury to the 
fetus, and thus hold promise in regenerative medicine.16–18 We 
previously reported that AFSC have an intermediate phenotype 
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between hESC and adult stem cells but are not pluripotent, although 
they can differentiate into non-mesodermal lineages.18 Here, we 
show for the first time that functional pluripotent human first-
trimester AFSC which express OCT4, SOX2, KLF4, c-MYC, and 
hESC-specific surface antigens, can be generated without ectopic 
reprogramming factors by culture on Matrigel in hESC medium 
supplemented with the histone deacetylase inhibitor (HDACi) val-
proic acid (VPA). Together, our data show that AFSC can be used 
to generate patient-specific pluripotent cells for use in regenerative 
medicine, pharmaceutical screening, and in disease modeling.
results
Human first-trimester AFsc have high kinetics 
and grow as compact colonies
Human first-trimester AFSC were expanded over 60 days on 
Matrigel-coated plates in low growth factor hESC feeder-free 
culture medium that enables expansion of pluripotent stem cells 
(Nutristem; Stemgent, San Diego, CA). Cells were first selected 
based on plastic adherence to eliminate hematopoietic cells and 
were subsequently selected based on c-KIT expression, as previ-
ously described by us.18 The fetal origin of the cells was confirmed 
in male samples by the presence of the SRY gene (Supplementary 
Figure S1a) and fluorescence in situ hybridization for the X and 
Y chromosomes (Supplementary Figure S1b). All cells expressed 
the stem cell growth factor receptor c-KIT, as seen by confo-
cal immunofluorescence and flow cytometry (Supplementary 
Figure S1c), were negative for the hematopoietic markers CD14, 
CD34, and CD45, showed low/null levels of HLAI and HLAII 
(Supplementary Figure S1d), and expressed the mesenchymal 
stem cell (MSC) markers CD73, CD44, CD105, CD29, fibronectin, 
laminin, and CD90 (Supplementary Figure S1e), but not CD24, a 
marker expressed in hESC but not in MSC (Supplementary Figure 
S1f).19 The AFSC population grew as compact spherical colonies 
of small cells, which were difficult to disaggregate and with time 
increased in size on top of large fibroblastic cells arranged as flat 
colonies (Supplementary Figure S2a). Growth kinetics analysis of 
cells started at passage 5–10 and showed exponential growth over 
70 days, reaching a total of 93 population doublings without any 
signs of slower proliferation or senescence, with a doubling time 
of 16.9 ± 1.9 hours (Supplementary Figure S2b). They underwent 
successful freeze-thaw cycles without modification of morphology 
or proliferation rate (data not shown). This high expansion poten-
tial was associated with long telomeres (Supplementary Figure 
S2c) and active telomerase (Supplementary Figure S2d). In all 
samples tested (passage 20), whole genome array analysis did not 
identify any aberrations larger than 100 kb, besides known benign 
copy number variations (http://projects.tcag.ca/variation/) indi-
cating karyotypic normality and stability after long-term in vitro 
cell expansion (Supplementary Figure S2e).
First-trimester AFsc share 82% transcriptome 
identity with hesc
We used the Illumina platform to profile the transcriptomes of 
AFSC (passage 15–20) and compared it to hESC. Hierarchical clus-
tering (Pearson’s correlation) using the overall expression data of 
each sample revealed distinct clustering of samples, which were 
clearly separated from hESC (Figure 1a). On the basis of detected 
gene expression signals, a Venn diagram was generated to highlight 
overlapping and distinct gene expression patterns in AFSC versus 
hESC. This led to the identification of an AFSC cell-specific gene 
expression signature comprising 740 genes, which include PRDM1/
BLIMP1 and ZPB2. The overlap between AFSC and hESC com-
prises of 7,905 genes, which corresponded to an 82% homology 
(Figure 1b). The hESC gene expression signatures were entered 
into the DAVID database to annotate functionally the single genes 
and identify potential enrichment of gene clusters corresponding to 
known signaling pathways. As illustrated in Supplementary Table 
S1, the set of 7,905 genes expressed in common between AFSC and 
hESC included 46 genes annotated as being expressed in the blad-
der, 383 in fetal brain, 53 in embryonic kidney, 183 in T-cells, 522 
in pancreas, 1,023 in liver, 771 in kidney, 430 in bone marrow, 345 
in platelets, 489 in ovaries, 3,667 in brain, 1,406 in lungs, and 545 
in muscles. The identification of potential enrichment of gene clus-
ters corresponding to known signaling pathways also confirmed 
that the undifferentiated state of AFSC partly depends on auto-
crine basic fibroblast growth factor (bFGF) signaling. Expression 
of OCT4, NANOG, SOX2, c-MYC, and KLF4 were confirmed by 
reverse transcription-PCR (RT-PCR) (Figure 1c).
the human first-trimester AFsc population 
is heterogeneous with regard to cell size and 
expression of sseA3, trA-1-60, trA-1-81, and AlP
Flow cytometry analysis of the AFSC population showed a bimodal 
distribution of the cells size, confirmed in light microscopy images 
of single cell suspensions, revealing two distinct groups of smaller 
and larger cells (circled respectively in red and blue in Figure 2a) 
(mean 12.0 ± 0.32 μm; median 11.51 μm, ranging from minimum 
8.00 μm to maximum 15.01 μm; n = 200) (Figure 2a). AFSC were 
positive for alkaline phosphatase (ALP), with staining almost exclu-
sively restricted to the compact colonies (Figure 2b). Confocal 
immunofluorescence showed that cells were positive for OCT4, 
NANOG, SOX2, KLF4, and SSEA4 (Figure 2c and Supplementary 
Figure S3). We observed that the staining was not uniform, as is 
the case for hESC, with cell-to-cell staining intensity varying within 
any one image. Moreover, for SSEA3, TRA-1-60, and TRA-1-81, we 
found both negative and positive cells (Figure 2c). Flow cytometry 
data confirmed expression of OCT4, NANOG, SOX2, c-MYC, and 
SSEA4 in AFSC, showing heterogeneity of the population, in agree-
ment with the immunostaining images which showed non-uniform 
expression of these markers, and the presence of SSEA3, TRA-1-60, 
and TRA-1-81 in only a subset of the whole population (respec-
tively, 64.1, 64.0, and 67.9% positive, circled in red in Figure 2d).
Bimodal heterogeneity of the population at the cell 
size level co-segregates with the expression of sseA3, 
trA-1-60, trA-1-81, and AlP
To investigate this heterogeneity further, SSEA3+ and SSEA3− cells 
were separated using MACS MicroBeadsTechnology. We found that 
the SSEA3− fraction corresponded to the larger cells (Figure 2e) 
while the smaller cells were contained within the SSEA3+ fraction, 
as evident in the flow cytometry scatters and the light microscopy 
images from cell suspension after separation (Figure 2f). We also 
found that all TRA-1-60+, TRA-1-81+, ALP+ cells were exclusively 
contained within the SSEA3+ fraction and that all SSEA3+ cells 
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were also positive for TRA-1-60, TRA-1-81, and ALP (Figure 2g). 
Coexpression of OCT4, NANOG, SOX2, c-MYC, and KLF4 at a 
single cell level was further confirmed in clonally derived cell lines 
derived from single SSEA3+ cells picked under microscopic con-
trol (Figure 2g). SSEA3+ and SSEA3− fractions were then plated 
either separately or in a co-culture setting. After cell attachment on 
the culture dish, SSEA3− cells showed a fibroblastic morphology 
with spindle cytoplasm and proliferated without forming colonies 
(Figure 2g). In contrast, SSEA3+ cells plated on Matrigel failed to 
proliferate, but they attached and grew when seeded in an insert 
above SSEA3− cells (or vice versa), indicating that the growth of 
SSEA3− cells provides functional support for the SSEA3+ cells. 
When the SSEA3− cell fraction was allowed to expand over 2 weeks, 
compact colonies spontaneously appeared, this population gave rise 
to cells positive for SSEA3, TRA-1-81, and TRA-1-60 in relative pro-
portion to the original parental AFSC population, indicating that the 
SSEA3 positive and negative subsets coexist in equilibrium within 
the AFSC population.
Human first-trimester AFsc form embryoid bodies
Since AFSC expressed OCT4, SOX2, c-MYC, and KLF4, we 
next investigated the pluripotency of the cells. When grown in 
suspension in permissive media in low attachment Petridish, AFSC 
readily acquired a spherical appearance within 1–2 days. After 2–3 
weeks, these aggregates of variable diameter were bigger in size 
and presented a more complex appearance, some forming a hollow 
ball while presenting a peripheral lining (Figure 3a). Within these 
embryoid bodies (EBs), cells expressed markers representative of 
the three embryonic germ layers, i.e., NESTIN and PAX6 (ecto-
derm), BMP4 (primitive endoderm), CK3, CK19 (endoderm), 
GATA6 (mesoderm), or SYCP1 (testis), with concomitant down-
regulation of OCT4A (Figure 3b). Confocal microscopy further 
confirmed expression of lineage markers of the three germ layers 
and showed the characteristic formation of the peripheral layer 
on the outer surface of the EBs, which exclusively contained cells 
expressing laminin (Figure 3c). Finally, cells organized in similar 
structures were observed contracting rhythmically in synchrony, 
mimicking a primitive cardiosphere appearance (Supplementary 
Video S1). Driven by the results obtained in culture, signs of 
in vivo pluripotency were investigated. However, when injected 
subcutaneously in the dorsal flank of 8–12-week-old common g 
chain−/− RAG2−/− C5−/− immunodeficient mice without precon-
ditioning (n = 5, positive control hESC), AFSC failed to develop 






















Figure 1 transcriptome analyses of first-trimester AFsc and hesc using the Illumina platform. (a) Hierarchical clustering of AFSC (samples 77, 
78, and 79) and hESC (H1 and H9) according to Pearson’s correlation. (b) Venn diagram based on detected genes in AFSC and hESC portraying 
distinct and overlapping transcriptional signatures between cell types. (c) RT-PCR of mRNA expression for OCT4, NANOG, SOX2, c-MYC, KLF4, and 
GAPDH in AFSC. Positive controls (+ve) were hESC and negative controls (−ve) were adult bone marrow MSC primers are listed in supplementary 
table s2. AFSC, amniotic fluid stem cell; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; hESC, human embryonic stem cell; MSC, mesenchy-
mal stem cell; RT-PCR, reverse transcription-PCR.
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Figure 2 Heterogeneity of the first-trimester AFsc population. (a) Flow cytometry plot of unstained AFSC confirmed the presence of both small 
(circled in red) and larger (circled in blue) granular cells. On the right, representative phase-contrast image of AFSC in suspension showing the pres-
ence of small (S) and larger (L) cells. (b) Alkaline phosphatase (ALP) staining of AFSC. MSC cells were used as a negative control and hESC as positive 
control, refer to supplementary Figure s4. (c) Confocal images, positive, and negative controls shown in supplementary Figure s3. Nuclei were 
stained with DAPI (blue). Bar, 50 μm. Antibodies listed in supplementary table s3. (d) Flow cytometry, isotype control in black. (e) Flow cytometry 
of the SSEA3+ fraction after MACS separation, phase-contrast image of single cells in suspension and ALP staining. Flow cytometry for SSEA3, TRA-
1-60, and TRA-1-81 (isotype control in black). (f) Flow cytometry of the SSEA3− fraction after separation, phase-contrast image of single cells in 
suspension and ALP staining. Flow cytometry for SSEA3, TRA-1-60, and TRA-1-81 (isotype control in black). RT-PCR of mRNA expression for OCT4, 
NANOG, SOX2, c-MYC, KLF4, and GAPDH in two clones C1 and C2. Positive controls (+ve) were hESC and negative controls (−ve) were adult bone 
marrow MSC primers are listed in supplementary table s2. (g) Phase contract microscopy showing that the SSEA3+ fraction only grows when 
co-cultured with the SSEA3− fraction while the latter expands without the SSEA3 positive cells. AFSC, amniotic fluid stem cell; DAPI, 4′,6-diamidino-
2-phenylindole; FSC, forward scatter; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; hESC, human embryonic stem cell; MACS, magnetic-
activated cell sorting; MSC, mesenchymal stem cell; RT-PCR, reverse transcription-PCR; SSC, side scatter.
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First-trimester AFsc generate teratomas upon VPA 
supplementation
Upon supplementation of the culture medium with VPA, a HDACi, 
AFSC (AFSC_VPA) were capable of forming teratoma following 
injection into immunocompromised mice. Investigation of opti-
mal VPA supplementation (concentration, i.e., 0.5–10 mmol/l, and 
length of supplementation, i.e., 1–10 days, data not shown)20 showed 
that treatment with 1 mmol/l VPA for 5 days is sufficient for confer-
ring teratoma formation competency to AFSC_VPA. Accordingly, 
2–3 × 106 cells cultured for 5 days in hESC medium supplemented 
with 1 mmol/l VPA were injected subcutaneously into immuno-
deficient mice. Within 8–10 weeks, AFSC_VPA formed encapsu-
lated cystic masses at the injection site that were easy to extract and 
were found to contain solid tissues of human origin (Figure 3d). 
Histopathological analysis revealed the presence of cell and tissue 
derivatives from all three embryonic germ layers, including neural 
tube and squamous epithelium (ectoderm), collagenous tissue and 
blood vessels of human origin (mesoderm), and alveolar and gut 
epithelium (endoderm) (Figure 3e). Immunohistochemical stain-
ing of the teratomas for differentiation markers further confirmed 
the presence of ectoderm-, mesoderm-, and endoderm-specific 
antigenic markers (Figure 3f).
VPA supplementation upregulates the expression 
of pluripotency-associated genes
Next, we explored the molecular mechanisms underlying the 
effects of VPA on AFSC. AFSC not cultured with VPA expressed 
OCT4, NANOG, and SOX2 at levels significantly lower than 
in hESC, whereas KLF4 and c-MYC levels were significantly 
higher (Figure 4a). However, supplementation with VPA led to 
an upregulation of OCT4, NANOG, and SOX2 (Figure 4a), with 
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Figure 3 embryoid body (eB) and teratoma formation from first-trimester AFsc cultured in nutristem supplemented with VPA for 5 days. 
(a) Phase-contrast image of EBs from AFSC showing peripheral lining, indicated by arrow. (b) RT-PCR in AFSC cultures (undifferentiated, U) and in 
two EBs (1 and 2) primers are listed in supplementary table s2. (c) Confocal immunofluorescence staining of EBs embedded in paraffin for Gata4, 
aFP, Nestin, Laminin, and Map2. Nuclei were stained with DAPI (blue). *Example of positive cell. Bar, 50 mm. (d) Human AFSC were subcutaneously 
injected into immunodeficient mice and formed teratomas. (e) Histological sections stained with hematoxylin and eosin showing the presence of 
various tissues derived from three germinal layers: neuronal epithelium (arrow indicating neural tube), squamous epithelium (ectodermal derivatives), 
bone, cartilage (arrow indicating collagen deposits) and blood vessels (mesodermal derivatives), alveolar tissue (arrow indicating blood islands), 
and intestinal epithelium (arrow indicating intestinal villi) (endodermal derivatives); neural tube and epithelium and keratinizing epithelium (ecto-
derm derivates), cartilage (mesoderm derivate), blood island and smooth muscles, gut epithelium and glandular tissue (mesoderm derivates). (f) 
Immunohistochemistry of sections stained with antibodies (as indicated) targeting cells and tissues derived from the ectoderm (top panel), mesoderm 
(middle panel), and endoderm (bottom panel) respectively. All images were acquired at ×40 (immunohistochemistry) or ×20 (histology) magnifica-
tion from a Zeiss Axiovert inverted fluorescence microscope. AFSC, amniotic fluid stem cell; DAPI, 4′,6-diamidino-2-phenylindole; RT-PCR, reverse 
transcription-PCR; VPA, valproic acid.
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12.2 ± 1.2 to 85.3 ± 5.3% for NANOG, and from 55 ± 8.2 to 164 
± 22.3% for SOX2, whereas KLF4 increased from 360 ± 19.5 to 
705.4 ± 16.2% and c-MYC from 26,950 ± 750 to 34,200 ± 350% 
(Figure 4a). As expected, although c-MYC expression level was 
considerably higher than hESC in undifferentiated AFSC_VPA, 
c-MYC expression dropped to 0.005 ± 350% upon differentiation 
(Figure 4a). At the protein level, flow cytometry showed high 
peaks of expression for OCT4, SOX2, and c-MYC, indicating uni-
form expression within the culture, with AFSC_VPA having lost 
bimodal expression of SSEA3, SSEA4, TRA-1-60, and TRA-1-81 
(Figure 4b).
VPA activates 585 specific genes, including 273  
hesc-specific genes
Transcriptome profiling of AFSC cultured with VPA (AFSC_VPA) 
showed that VPA-treated samples (AFSC_VPA 1 and AFSC_VPA 
2) clustered together and were clearly separated from both of their 
respective parental lines (AFSC 77, AFSC 78, and AFSC 79), as well 
as from hESC (Figure 4c). On the basis of detected gene expression 
signals (detection P value <0.01) a Venn diagram was generated 
to highlight overlapping and distinct gene expression patterns in 
AFSC versus AFSC_VPA and hESC (Figure 4d). This revealed 
an overlap between AFSC_VPA and hESC of 7,572 genes, among 
which 273 genes were only expressed in AFSC_VPA and hESC 
but not in AFSC. In addition, 312 genes were uniquely expressed 
in VPA_AFSC but not in hESC nor in AFSC (Figure 4d).
The identification of potential enrichment of gene clusters cor-
responding to known signaling pathways showed that the enriched 
273 genes set common to AFSC_VPA and hESC but not expressed in 
AFSC was associated with WNT and NOTCH signaling pathways, 
and included genes expressed during spermatogenesis, including 
testis-specific kinase 2 (TESK2), gamete generation, sexual repro-
duction, as well as genes expressed during embryonic development, 
patterning, neurogenesis and development of the nervous system, 
immunoglobulins, negative regulation of cell death and apopto-
sis, cell signaling, development of kidney, limb, urogenital system, 
mesoderm, primary germ layer, gastrulation, tissue morphogenesis, 
and regulation of transcription and gene expression, as well as genes 
involved in chromatin binding, histone modification, and chro-
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Figure 4 transcriptome analysis of first-trimester AFsc culture in nutristem supplemented with VPA for 5 days. (a) Quantitative real-time RT-PCR. 
The relative expression of OCT4, NANOG, SOX2, c-MYC, and KLF4 was normalized by its expression in hESC (H9 line) after normalization to β-actin and 
plotted (log10 scale) relative to the expression level in H9, arbitrarily set to 100. Error bars, SEM, n = 4 primers are listed in supplementary table s2. 
(b) Flow cytometry analyses, isotype control in black. (c) Hierarchical clustering of AFSC (samples 77, 78, and 79), AFSC cultured with VPA (AFSC_VPA1 
and AFSC_VPA2), and hESC (H1 and H9) according to Pearson’s correlation. (d) Venn diagram based on detected genes in AFSC, AFSC_VPA, and hESC 
portraying distinct and overlapping transcriptional signatures between cell types. AFSC, amniotic fluid stem cell; hESC, human embryonic stem cell; 
RT-PCR, reverse transcription-PCR; VPA, valproic acid.
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genes involved in the extracellular matrix production were enriched 
in AFSC_VPA following VPA treatment.
In the 312 AFSC_VPA-specific genes signature, Jak-STAT sig-
naling, cytokine-cytokine receptor, γ-R–mediated phagocytosis, 
and vascular smooth muscle contraction were over-represented. In 
addition AFSC_VPA, but not AFSC or hESC, uniquely expressed 
VCX3A, which is involved in spermatogenesis and is exclusively 
expressed in male germ cells; C19ORF20, which is required for 
the development of the spermatid flagellum; as well as MICALCL, 
which is involved in the morphogenetic development of round 
spermatids to spermatozoa.
This raised the possibly that AFSC might originate from a 
founder population of stem cells of epiblast origin such as pri-
mordial germ cells, which may have been retained in the amniotic 
fluid early during their migration to the genital ridges. The epiblast 
origin of AFSC was further documented during whole genome 
transcriptome analysis by high expression of FGF5, a marker of 
pluripotent epiblast cells which is not expressed in the inner cell 
mass. In fact, c-KIT is expressed on the surface of primordial 
germ cells, neural crest stem cells and hematopoietic stem cells. 
The transcriptome of AFSC_VPA showed absence of expression 
of markers which constitute the neural crest stem cell molecular 
signature, such as FOXD3 and RET, indicating that AFSC might 
be of primordial germ cells/progenitors origin.
expanded AFsc_VPA have a stable phenotype
To further analyze the stability of the phenotype of AFSC_VPA and 
investigate their full pluripotency, cells were cultured for 6 weeks fol-
lowing the initial 5 days of VPA supplementation (Figure 5a). Flow 
cytometry showed that the changes in pluripotency gene expression 
induced by VPA supplementation were stable over time, as seen 
by the single peaks of expression for OCT4, SOX2, c-MYC, SSEA3, 
SSEA4, TRA-1-60, and TRA-1-81 (Figure 5b). In addition, expanded 
AFSC_VPA were positive for CD24, a marker also associated with 
pluripotent hESC and not present in MSC21 (Figure 5c). Cells also 






















































































137 Days in culture
SOX2 C-MYC SSEA3 SSEA4 TRA-1-60 TRA-1-81
Figure 5 characteristics of first-trimester AFsc after expansion over 6 weeks on Matrigel in nutristem medium following VPA supplementa-
tion. (a) Timescale showing culture medium of first-trimester AFSC of 90 days expansion in vitro. (b) Flow cytometry analyses for OCT4, SOX2, c-MYC, 
SSEA3, SSEA4, TRA-1-60, and TRA-1-81, isotype control in black. (c) Flow cytometry analyses for CD24, CD29, and CD90, isotype control in black. (d) 
Confocal immunostaining for REX1. Nuclei were stained with DAPI (blue). Bar, 100 μm. (e) Doubling time (hours) of adult bone marrow MSC (aMSC), 
and AFSC either expanded in Nutristem without VPA supplementation (AFSC) or following VPA supplementation (AFSC_VPA) after 90 days in culture. 
***P < 0.001. (f) Quantitative real-time RT-PCR showing relative expression of Xist in ESC, and AFSC either expanded in Nutristem supplemented with 
VPA for 5 days (95 days) and after further 6 weeks in culture (137 days), or in AFSC differentiated down the osteogenic pathway (differentiated). (g) 
Quantitative real-time expression of AFSC before and after VPA treatment for 5 days (95 days) and after 6 weeks of expansion (137 days). Positive 
control, hESC and negative control, aMSC. (h) Karyotype of AFSC after 90 days in culture on Matrigel in Nutristem medium following VPA supplemen-
tation. AFSC, amniotic fluid stem cell; DAPI, 4′,6-diamidino-2-phenylindole; ESC, embryonic stem cell; FITC, fluorescein isothiocyanate; hTERT, human 
telomerase reverse transcriptase; MSC, mesenchymal stem cell; NS, not significant; RT-PCR, reverse transcription-PCR; VPA, valproic acid.
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MSC (Figure 5c),19 as well as REX1, a known marker of undifferenti-
ated hESC which is a direct target of NANOG augmented by SOX2 
and OCT422 (Figure 5d). In addition, AFSC_VPA showed stable 
growth with an averaged population doubling of 21 ± 3.4 hours after 
6 weeks in culture (Figure 5e). Finally, female AFSC_VPA showed 
X-chromosome inactivation repression, as seen by the repression 
of the X-linked Xist gene, the expression of which is essential for 
heterochromatin formation on the X chromosome (Figure 5f).23 
Expression of a subset of X-linked genes in our gene arrays showed 
that CXORF15, PLS3, RBBP7, and UTX were expressed, confirm-
ing repression of X-chromosome inactivation in AFSC_VPA. In 
addition, AFSC_VPA maintained expression of human telomerase 
reverse transcriptase (hTERT), which encodes the catalytic and a 
rate-limiting subunit of telomerase (Figure 5g) and were genetically 
stable (Figure 5h). Finally, transcriptome identity of AFSC_VPA 
showed that, similarly to hESC but contrary to the parental line, 
AFSC_VPA expressed tripartite motif protein 28 (TRIM28), also 
known as transcription intermediary factor 1β (TIF1β) or KRAB-
associated protein 1 (KAP1), which is a specific and indispensable 
factor for the maintenance of pluripotency in hESC.24
expanded AFsc_VPA differentiate into endoderm, 
mesoderm, and ectoderm
We next investigated the capacity of AFSC_VPA to differenti-
ate into specific lineages of the three germ layers after 6 weeks 
of expansion. We first directed AFSC towards definitive endo-
derm by culturing the cells in the presence of Activin-A under 
serum-free condition for 5 days. As determined by quantitative 
real-time RT-PCR, cells showed upregulation of genes expressed 
in the definitive endoderm such as SOX17, GSC, and HNF-3β, 
and downregulation of the extraembryonic endoderm marker 
SOX7, indicating that expression of the above markers was the 
result of differentiation into definitive but not primitive endo-
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Figure 6 First-trimester AFsc cultured in permissive medium expressed markers of endoderm- and mesoderm-derived lineages. (a) 
Quantitative real-time RT-PCR showing relative expression of the definitive endoderm markers HNF-3β, GSC, SOX17 and the primitive endo-
derm marker SOX7 in AFSC at day 0 and at day 4 after culture in definitive endoderm differentiation medium. ***P < 0.001 primers are listed 
in supplementary table s2. (b) Flow cytometry for cell surface CXCR4-PE showing relative AFSC number at day 0 and day 4 after culture in 
definitive endoderm differentiation medium (isotype control in black). ***P < 0.001.(c) Confocal immunostaining for SOX17 and HNF-3β in AFSC 
at day 0 and day 4 after culture in definitive endoderm differentiation medium. Nuclei were stained with DAPI (blue). Bar, 50 μm. (d) Confocal 
immunostaining for ALBUMIN and AFP. Nuclei were stained with DAPI (blue). Bar, 50 μm. (e) Urea production (mmol/l) by AFSC undifferentiated 
or after 2 weeks of differentiation into hepatocyte permissive medium. ***P < 0.001. AFP, α-fetoprotein; AFSC, amniotic fluid stem cell; DAPI, 
4′,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate; RT-PCR, reverse transcription-PCT; undif., undifferentiated.
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significant increase in the number of cells expressing CXCR4 on 
the cell surface (Figure 6b), and confocal immunostaining con-
firmed expression of SOX17 and HNF-3β in cells cultured in the 
presence of Activin-A (Figure 6c), indicating that AFSC_VPA 
differentiated into definitive endoderm.
Culture of AFSC_VPA in hepatic-permissive medium supple-
mented with hepatocyte growth factor over 21 days induced expres-
sion of the hepatic markers ALBUMIN and AFP (α-fetoprotein) as 
visualized by confocal immunostaining (Figure 6d). Functionality 
of the differentiated cells was evidenced by the production of urea 
in the culture medium (Figure 6e).
Differentiation into the three standard mesodermal lineages, 
i.e., osteogenic, chondrogenic, and adipogenic, was confirmed 
by Von Kossa (osteogenic), Alcian blue (chondrogenic), and oil-
red-O (adipogenic) stainings, and by expression of the appropriate 
lineage-specific markers osteopontin (osteogenic), collagen type 
II (ColII), and PPARγ (adipogenic) (Supplementary Figure S4).
To investigate whether AFSC_VPA can undergo neuraliza-
tion, cells were first cultured in a serum-free chemically defined 
medium supplemented with epidermal growth factor (EGF), 
bFGF, and leukemia inhibitory growth factor (LIF), which have 
been shown to stimulate expansion of hESC-derived neural 
stem cells.25 AFSC_VPA grew rapidly as adherent cells, showed 
bipolar morphology, and expressed NESTIN and VIMENTIN 
(Figure 7a), but not mesoderm markers BRACHYURY, neither 
the endoderm marker FOXA2 (negative results not shown). 
When co-cultured with C17.2 mouse neural progenitor cells in 
chemically defined medium supplemented with Baicalin for 21 
days, AFSC_VPA changed morphology and expressed the neu-
ronal markers β-tubulin and the microtubule-associated protein 
2 (MAP2) (Figure 7b) and the NMDA receptor NR1 (Figure 7c). 
When AFSC_VPA were co-cultured in the presence of CG4 rat 
oligodendrocyte progenitor cells in chemically defined medium 
supplemented with bFGF, platelet-derived growth factor (PDGF), 
and B104-conditioned medium for 21 days, cells changed mor-
phology and expressed the oligodendrocyte-specific markers O4 
and NG2 (Figure 7d). In all differentiation setting, expression of 
lineage-specific makers was concomitant with downregulation of 
OCT4 and NANOG (negative results not shown).
AFsc cells share common features with primordial 
germ cells/precursors
We next investigated the hypothesis that the AFSC population 
includes primordial germ cell (PGC) or PGC precursors. We showed 
that AFSC expressed the PGC markers c-KIT, T, FGF8, SOX17, 
STELLA, DAZL, NANOS2, NANOS3, VASA, SSEA1, FRAGILIS, 
and PUM2 (Figure 8a). However, AFSC did not expressed ERAS, 
which is repressed in PGC26 (Figure 8a). At the protein level, the 
population contain cells positive for FRAGILIS, SSEA1, TNAP, 
NANOS, BLIMP1, PUM2, STELLA, DAZL, and VASA (Figure 8b). 
Interestingly, SSEA1, which is expressed in human PGC but not in 
hESC, was expressed in AFSC. Tissue nonspecific alkaline phos-
phatase (TNAP) was strongly expressed in the cytoplasm; BLIMP1, 
a transcriptional repressor expressed in the nucleus of PGC which 
progressively relocates to the cytoplasm during migration of PGC 
to the genital ridge but is absent in embryonic germ cells,27 was 
expressed in the cytoplasm of AFSC cells; FRAGILIS and STELLA 
were expressed in both nucleus and cytoplasm, as is the case for 
PGCs;28 NANOS, DAZL, which is known to relocate from the 
nucleus to the cytoplasm in human fetal germ cells and PUM229 
were expressed in the cytoplasm. In migratory PGC, this relocation 
with parallel downregulation of OCT4 and the onset of expression 
of VASA, which in AFSC is expressed in the cytoplasm, indicating 
that AFSC might be related to PGC, which have been retained in 
the amniotic fluid early at the start of their migration to the geni-
tal ridge.30 With the exception of VASA, we noticed that AFSC did 
not show uniform staining for the other PGC markers on immu-
nofuorescence images, with the presence of cells either negative or 
weakly positive. As visualized by flow cytometry, the percentages of 
positive cells in the culture were respectively 63.9% for FRAGILIS, 
53.9% for SSEA1, 52.2% for TNAP, 47.4% for NANOS, 37.1% for 
BLIMP1, 49.3% for PUM2, 83.9% for STELLA, 51.6% for DAZL, 
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Figure 7 First-trimester AFsc cultured in permissive medium expres-
sed ectodermal and neuronal markers. Confocal immunostaining for 
the ectoderm markers (a) NESTIN and VIMENTIN, (b) neuronal mark-
ers β-TUBULIN and MPA2, (c) NMDA receptor NR1, and (d,e) oligoden-
drocyte markers O4 and NG2. Nuclei were stained with DAPI (blue). 
Bar, 50 μm. AFSC, amniotic fluid stem cell; DAPI, 4′,6-diamidino-2-
phenylindole; FITC, fluorescein isothiocyanate.
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Migration of PGC is characterized by a first decrease in DNA 
methylation, which initiates in migrating PGC. For example, the 
H19 differentially methylated domain (DMD) is methylated on the 
paternal allele only in all normal somatic cells and H19 DMD meth-
ylation is erased in PGCs which have reached the genital ridge.31 
To explore the status of the H19 DMD in AFSC, we first analyzed 
H19 expression, itself regulated by methylation at the H19 DMD. 
Of five samples, one was informative for the exonic rs2075745 
single-nucleotide polymorphism (SNP) in H19. We extracted RNA 
and carried out RT-PCR followed by Sanger sequencing, revealing 
monoallelic expression of H19 and mirroring the status of this tran-
script in somatic cells (Figure 8d). To explore methylation of the 
H19 DMD, we carried out bisulphite sequencing and revealed a 1:1 
























































SSEA1 TNAP NANOS BLIMP1 PUM2 STELLA DAZL VASA
FRAGILIS SSEA1 TNAP NANOS BLIMP1 PUM2 STELLA DAZL VASA
Molecular Therapy  vol. 20 no. 10 oct. 2012   1963
© The American Society of Gene & Cell Therapy
Pluripotency State of Amniotic Fluid Stem Cells
methylated:59 % unmethylated) (Figure 8e). These data are indica-
tive of allelic differential methylation at the H19 DMD, as expected 
from the monoallelic expression of H19 in AFSC. We next compared 
the whole genome transcriptome identity of AFSC_VPA with the 
seminoma cell line TCam-2,32 which exhibit characteristics of fetal 
germ cell (Supplementary Figure S5). Results showed that AFSC 
and TCam-2 cells share 39% transcriptome identity (Figure 8f).
dIscussIon
The direct reprogramming of somatic stem cells to pluripotency 
provided a valuable tool for pharmaceutical screening, disease 
modeling, and in cell-based therapies, although therapeutic appli-
cations are presently limited by the pitfalls associated with the use 
of vectors employed for generating iPSCs from terminally differ-
entiated somatic cells. Here, we show that human first-trimester 
amniotic fluid contains cells of germ origin that can be reverted 
to pluripotency when expanded on Matrigel in low growth fac-
tor medium supplemented with VPA. The AFSC population 
showed some features with MSC, such as expression of CD73, 
CD44, CD105, fibronectin, and laminin. However, the phenotype 
of AFSC is distinct from that of MSC as cells shared 82% tran-
scriptome identity with hESC, had high kinetics, expressed telom-
erase, and contained a subset of cells expressing the hESC-specific 
markers OCT4, NANOG, SSEA4, SOX2, KLF4, and c-MYC with 
60% of the cells also coexpressing SSEA3, TRA-1-60, TRA-1-81, 
and ALP at clonal level. AFSC grew as compact colonies of small 
SSEA3+ cells on top of larger SSEA3− cells growing as flat colo-
nies, with SSEA3+ cells proliferation being dependent on soluble 
factors secreted from SSEA3− cells which function as feeders. The 
SSEA3− AFSC population was capable of re-entering the stem cell 
compartment by acquiring SSEA3 expression, reflected in their 
ability to form mixed colonies of SSEA3−/+ cells. Interestingly, 
two subclasses of hESC based on SSEA3 expression33 have also 
been reported, with SSEA3+ hESC not proliferating in the absence 
of SSEA3− cells, which function as support, whereas the latter can 
be expanded successfully in the absence of SSEA3+ hESC.34
It has recently been emphasized that assessment of human 
pluripotent lines should be carried out through the highest-
stringency test acceptable, i.e., teratoma formation.35 Here, we 
show that upon supplementation with VPA, a HDACi which 
can induce pluripotency genes in hESC36 and has been found to 
enhance the efficiency of iPSC production,37 AFSC_VPA homo-
geneously expressed OCT4, SOX2, KLF4, c-MYC, and the hESC-
specific surface antigens TRA-1-60, TRA-1-81, SSE3, and SSEA4, 
stained positive for ALP, readily formed embryoid bodies in vitro 
and generated teratomas in vivo. Interestingly, TRA-1-81 expres-
sion has been used for the identification of genuine human iPSC 
colonies derived from fibroblasts.38 The pluripotent phenotype of 
AFSC_VPA was stable over time, as seen by the cells retaining 
a normal phenotype and maintaining expression of pluripotency 
markers, high kinetics, normal karyotype, telomerase activity, 
repression of X-inactivation, and ability to differentiate into func-
tional lineages of the three germ layers, i.e., bone, fat, cartilage, 
definitive endoderm, hepatocyte, ectoderm, neurons, and oligo-
dendrocytes. Although together these results are in accordance 
with true pluripotency, additional assays would be beneficial in 
testing the functional differentiation and tissue repair capac-
ity of specific cell types derived from AFSC_VPA in transplant 
models.35
Despite pluripotent AFSC_VPA sharing common charac-
teristics with hESC, including similar levels of expression of 
OCT4, SOX2, and NANOG, active telomerase, repression of 
X-inactivation, high cell-division kinetics, and capacity to dif-
ferentiate into lineages of the three germ layers, they also present 
unique features, such as higher levels of c-MYC and KLF4 expres-
sion, and 18% of unique transcriptome identity. c-MYC expression 
has been shown to maintain ES pluripotency and self-renewal, 
and is required for early embryogenesis, controlling proliferation 
versus differentiation.39 Our results show that upon differentia-
tion, the levels of c-MYC expression are downregulated, indicat-
ing that the derivates of AFSC_VPA potentially used in cell-based 
therapies may not be oncogenic.
The analysis of the molecular mechanisms involved in the 
effects of VPA revealed that VPA-treated AFSC expressed 273 
genes in common with hESC, among which 13 genes are involved 
in the extracellular matrix production. Interestingly, it was recently 
shown that increased pluripotency of hESC by HDAC inhibition 
acts to enhance the activity of target genes involved in extracel-
lular matrix production to support pluripotency.36 In addition, 
VPA-treated AFSC uniquely expressed 312 genes including genes 
involved in spermatogenesis that are only expressed in germ 
cells. Complementary analysis revealed that AFSC share com-
mon characteristics with PGC or PGC precursors, expressing 
c-KIT, T, FGF8, SOX17, STELLA, DAZL, NANOS, VASA, SSEA1, 
FRAGILIS, STELLA, and PUM2. However, AFSC have not lost 
their imprinting and therefore might originate from PGC or PGC 
progenitors, which have been retained in the amniotic fluid at the 
start of their migration to the genital ridge, when imprinting is not 
yet erased, and remained undifferentiated probably because they 
miss two key messages for cell differentiation such as cell-matrix 
Figure 8 First-trimester AFsc population manifest features of primordial germ cells (PGc)/progenitors. (a) RT-PCR of mRNA expression for 
c-KIT, ERAS, T, FGF8, SOX17, STELLA, DAZL, NANOS2, NANOS3, VASA, SSEA1, FRAGILIS, PUM2, and GAPDH. (b) Confocal immunofluorescence images 
showing AFSC expressing FRAGILIS, SSEA1, TNAP, NANOS, BLIMP1, PUM2, STELLA, DAZL, and VASA. Nuclei were stained with DAPI (blue). Bars, 
100 μm. (c) Flow cytometry for PGC markers in AFSC cells. Isotype control in black. (d) Analysis of allelic expression of the H19 gene. Genomic 
and cDNA Sanger sequencing chromatograms are shown in the H19 SNP rs2075745. The SNP is highlighted in red, showing complete monoal-
lelic expression from this sample in the cDNA. *Single peak at nucleotide C. (e) Bisulphite sequencing of the H19 differentially methylated domain 
(DMD). Closed circles indicate methylated CpG dinucleotides and open circles represent unmethylated CpG dinucleotides. The even distribution of 
methylated and unmethylated strands for this region (41% methylated:59% unmethylated) is indicative of the maintenance of normal differential 
methylation at the H19 DMD. Quality control of bisulphite sequencing data was performed in a standardized manner using BiQ analyser. Bisulphite 
conversion was at least 90% in each case and any identical PCR clones were excluded. Bead on a string diagrams were produced using BiQ Analyser. 
(f) Venn diagram based on detected genes in AFSC, AFSC_VPA, and TCam-2 cells portraying distinct and overlapping transcriptional signatures 
between cell types. AFSC, amniotic fluid stem cell; DAPI, 4′,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; gDNA, genomic DNA; RT-PCR, reverse transcription-PCR; SNP, single-nucleotide polymorphism; VPA, valproic acid.
1964 www.moleculartherapy.org  vol. 20 no. 10 oct. 2012 
© The American Society of Gene & Cell Therapy
Pluripotency State of Amniotic Fluid Stem Cells
and cell-cell contacts. PGC originate from the pluripotent epiblast 
and migrate out of the embryo to reside in extra embryonic tissues 
where they subsequently migrate to the genital ridge once gastru-
lation is completed.40 Zwaka et al.41 have suggested a germ cell ori-
gin of hESC, providing evidence that the closest in vivo equivalent 
to hESC is early germ cells. It has also been hypothesized that dur-
ing early development, epiblast/germ line-derived cells including 
PGC become founder populations of stem cells.42
Reprogramming has been achieved from several easily acces-
sible adult somatic cell types using virus-free and/or vector-free 
methods.10 Here, we have avoided the use of virally/nonvirally 
introduced exogenous factors and have alternatively employed 
VPA, which is a US Food and Drug Administration–approved 
drug for the treatment of epilepsy43 and may therefore facilitate 
the generation and application of transgene-free reprogrammed 
cells in a clinical setting. We anticipate that early AFSC could pro-
vide alternative source of pluripotent cells. Similarly to other first-
trimester fetal stem cells, amniotic fluid can be collected early in 
pregnancy during termination procedure and pluripotent AFSC 
derived for allogeneic clinical use in cell-based therapies or in 
medicine for disease modeling and drug screening. Considering 
that a bank of 150 donor cell lines would provide a beneficial 
match for up to 37.9% of the population,44 these results may also 
have broader effect on society, promoting the development of 
banks of pluripotent cells of fetal origin. Further studies will also 
be needed to investigate whether similar cells could be found and 
expanded either from mid-gestation amniotic fluid, or from other 
extraembryonic tissues routinely sampled.
MAterIAls And MetHods
Ethics. The Research Ethics Committee of Hammersmith and Queen 
Charlotte’s Hospitals approved amniotic fluid collection. All animals 
were handled in strict accordance with good animal practice as defined 
by UK Home Office Animal Welfare Legislation, and all animal work was 
approved by the Institutional Research Ethics Committee (ICH, UCL, 
UK), under PPL 70/7024.
Cell culture. Amniotic fluid was collected between 10 and 12 weeks of ges-
tation (n = 12) under ultrasound guidance. Cells were first selected based 
on plastic adherence45 until confluency and subsequently selected for c-KIT 
expression as previously described by us.33 Cells were expanded (104 cells/
cm2) at 37 °C in 5% CO2 on Matrigel (Becton Dickinson, Oxford, UK) in 
Stemedia Nutristem XF/FF (Stemgent, San Diego, CA, USA) which sustain 
the pluripotency state of ES and iPS but do not support the growth of MSC, 
supplemented or not with VPA (1 mmol/l; Sigma-Aldrich, St Louis, MO). 
MSC were from Tulane Center for Gene Therapy (Tulane University, New 
Orleans, LA). ES cell lines H1 and H9 (WiCell Research Institute) were 
cultured in knockout Dulbecco’s modified Eagle’s medium (KO-DMEM) 
supplemented with 20% knockout serum replacement, 100 µmol/l nones-
sential amino acids, 2 mmol/l L-glutamine, 100 U/ml penicillin/streptomy-
cin, sodium  pyruvate, 0.1 mmol/l β-mercaptoethanol (Invitrogen, Carlsbad, 
CA), and 8 ng/ml bFGF (Peprotech, Rocky Hill, NJ) on mitomycin-c (Sigma-
Aldrich)-inactivated mouse embryonic fibroblasts. For comparative tran-
scriptome analysis, hESC were adapted to feeder-free culture conditions on 
Matrigel in mTeSR (Stemcell Technologies, Grenoble, France). ALP staining 
(Sigma-Aldrich) was performed according the manufacturer’s instructions.
TCam-2 cells were cultivated as previously described by us.32 Briefly, 
TCam-2 cells were grown in RPMI medium supplemented with 10% fetal 
calf serum, 1% penicillin/streptomycin, 200 mmol/l glutamine. The cells 
were grown at 37 °C and 5% CO2; 1× trypsin/EDTA (0.05%/0.02%) was 
used to detach cells during passaging.
Growth kinetics. Cells were plated in triplicates (1 × 104/cm2), trypsinized 
when subconfluent and replated at similar density after exclusion of dead 
cells. The doubling time (DT) was calculated as DT = t/(Log2(y/m)), t = 
time in culture, y = number of cells at end of culture, m = number of cells 
at beginning of culture.
DNA extraction and PCR. Genomic DNA was extracted as described46 
and PCR analysis carried out on Engine Opticon 2 using Opticon Monitor 
software (MJ Research, Hatboro, PA), 94 °C, 2 minutes; then 40 cycles of 
95 °C, 15 seconds; 60 °C, 30 seconds; 72 °C, 30 seconds. PCR reactions 
included 2X Sybr-Green PCR Mastermix (Sigma-Aldrich), 300 nmol/l 
primers and 2 µl of template in a 30 µl reaction volume. Each measure-
ment was performed in triplicate and data normalized to two housekeep-
ing genes (GAPDH and HPRT).
RT, RT-PCR, and real-time RT-PCR. Total RNA was extracted using the 
RNeasy Mini RNA kit (Qiagen, Valencia, CA) and cDNA synthesized 
using Pd(N)6 random hexamers (Amersham Pharmacia Biotech, St 
Albans, UK) and 1 ml of 200U M-MLV Reverse Transcriptase in the 
presence of dNTPs (Promega, Madison, WI). The cDNA was amplified 
by 30 cycles (94 °C, 60 seconds; 60 °C, 30 seconds; 72 °C, 30 seconds), 
followed by 72 °C for 5 minutes. For real-time protocols, we used SYBR 
Green dye fluorescence (Applied Biosystems, Foster City, CA) and the 
ABI Prism 7700 Sequence Detection system (Applied Biosystems). 
Samples were normalized against the internal control (28S) and plotted 
(log10 scale) relative to the expression level in hESC H9, arbitrarily set to 
100 (Supplementary Table S2).
X-inactivation. To examine the expression of Xist we used a Taqman 
Gene Expression assay (Applied Biosystems) according to manufactur-
ers’ instructions. H1 (male) and H7 (female) human ES cells were used as 
negative and positive control respectively.
Real-time PCR quantification of hTERT mRNA. Levels of hTERT expres-
sion were estimated by SYBR Green real-time quantification using primers 
and methods described by us previously.45 To normalize hTERT expression 
for intersample differences in RNA input, quality, and reverse transcriptase 
efficiency, we amplified the housekeeping gene β-actin. The ratio between 
copy numbers of hTERT mRNA and β-actin mRNA was used to normal-
ize the amount of hTERT mRNA for each sample and allowed comparison 
between samples. Positive control was hESC and negative control was adult 
bone marrow MSC.
Relative telomere length and telomerase activity. Relative telomere 
lengths and telomere activity were measured by real-time quantitative PCR 
amplification. The primers and thermal cycling profiles were adapted from 
Cawthon et al.47 and Wege et al.48 as previously described by us.45
Immunofluorescence. Cells were fixed in 4% PFA in 125 mmol/l HEPES 
(pH 7.6; 10 minutes, 4 °C) followed by 8% PFA in the same buffer (50 
minutes, 4 °C) and permeabilized in 0.5% Triton X-100 in phosphate-
buffered saline (PBS) (30 minutes). Cells were then rinsed in PBS, blocked 
(1 hour) with PBS+ (PBS supplemented with 1% bovine serum albumin, 
0.2% fish skin gelatin, 0.1% casein; pH 7.6), incubated (2 hours) with pri-
mary antibodies in PBS+, washed in PBS+, incubated (1 hour) with sec-
ondary antibodies in PBS+, washed (overnight, 4 °C) in PBS+, rinsed in 
PBS, and stained with DAPI before being mounted in VectaShield (Vector 
Labs, Burlingame, CA). Images were collected on a confocal laser-scan-
ning microscope Leica TCS SP5 (X1000 PL APO oil objective; Leica, 
Wetzlar, Germany) and transferred to Adobe Photoshop (Adobe Systems, 
Dublin, Ireland). All primary antibodies (Supplementary Table S3) were 
used at 1:10–1:100 dilutions. Secondary antibodies were donkey anti-
mouse and anti-rabbit IgG conjugated with FITC (1:100 dilution; Jackson 
ImmunoResearch Laboratories, West Grove, PA). Positive controls were 
hESC and negative controls were MSC.
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Flow cytometry. Cells were resuspended in FACS buffer (PBS, 1% bovine 
serum albumin; 5 × 105 cells/100 ml buffer). For cell surface staining, cells 
were stained with antibodies for 1 hour at 4 °C. When using unconjugated 
primary antibodies (mouse anti-human SSEA3, TRA-1-60 and TRA-1-81, 
and rabbit anti-human NANOG), cells were washed in FACS buffer and sec-
ondary goat anti-mouse IgM PE-conjugated or goat anti-rabbit IgG FITC-
conjugated antibody was added and incubated for 30 minutes. Cells were 
then washed and resuspended in FACS buffer. For intracellular FACS stain-
ing, cells were washed once in FACS buffer, fixed for 10 minutes in 0.01% 
PFA, washed twice with PBS, resuspended in permeabilization buffer (PBS, 
1% Triton) and stained as above. All samples were analyzed by FACScalibur 
flow cytometer (Becton Dickinson) and analyzed using CellQuest software. 
Positive controls were hESC and negative controls were IgG or IgM primary 
antibody-specific isotype controls (Supplementary Table S3).
EB formation. Cells from 5 to 6 confluent wells of a 6-well plate were incu-
bated with differentiation medium containing 80% KO-DMEM supple-
mented with 1 mmol/l L-glutamine, 0.1 mmol/l β-mercaptoethanol, 1% 
nonessential amino acids stock (all Gibco BRL Life Technologies, Grand 
Island, NY) and 20% fetal bovine serum (FBS) (Biosera, Ringmer, UK). At 
confluence, cells were incubated with 1 mg/ml type IV collagenase (Sigma-
Aldrich) at 37 °C for 10 minutes before being dissociated into small clumps 
using 100-ml Gilson pipette tips, cultured in suspension in 58-mm low 
attachment Petri dish in differentiating medium and allowed to develop 
into 15-day-old EBs. EBs suspensions were then transferred to gelatin-
coated plates for another 7–10 days before fixation in 4% PFA.
Teratoma formation assay. Immunodeficient mice were housed in microi-
solator laminar flow caging systems and were supplied with sterile water, 
food, and bedding; 2 × 106 cells resuspended in Matrigel were injected sub-
cutaneously into the dorsal flank of 8–12-week-old common γ-chain−/−, 
RAG2−/−,C5−/− immunodeficient mice without preconditioning. Mice were 
observed for the growth of solid tumors up to 12 weeks or up to 10 mm3 
tumor volume. All experiments were performed according to Home Office 
animal welfare legislation. Positive control was hESC.
Molecular analysis. Array comparative genomic hybridization was per-
formed using a 105K-oligonucleotide microarray (CytoSure Syndrome 
Plus v2; Oxford Gene Technology, Begbroke, UK). Labeling and hybridiza-
tion were performed following the manufacturer’s protocols (Invitrogen). 
After washing the array was analyzed with the Agilent scanner and Feature 
Extraction software (Agilent Technologies, Wokingham, UK) and text file 
outputs from the quantitation analysis were imported to CytoSure Interpret 
Software (Oxford Gene Technology).
Illumina bead chip hybridization and global gene expression analysis. 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen). For each sam-
ple, 500 ng RNA were used as input for the biotin-labelling reaction (IL1791; 
Ambion, Grand Island, NY). Bead chip hybridization, washing steps, Cy3-
straptavidin staining, and image scanning were performed on Illumina 
BeadStations 500 (Illumina, San Diego, CA). Basic processing of the resulting 
raw data was done using BeadStudio Software version 3.0.17. This included 
background subtraction and normalization of signal intensities according to 
the rank invariant algorithm. Significant expression values were determined 
by comparison with negative control beads. Hierarchical clustering based on 
Pearson’s correlation was performed for overall expression data. For the gen-
eration of Venn diagrams, detected gene expression was defined by a detec-
tion P Value <0.01. The DAVID platform version 6.7 was used to perform 
functional annotation and signaling pathway and tissue expression enrich-
ment analyses (http://david.abcc.ncifcrf.gov/home.jsp) (Huang et al., 2009). 
Illumina PROBE_IDs and/or Official Gene Symbols were used as input 
against the background of the Homo sapiens species. Analyses were per-
formed using DAVID default parameter settings (14 December 2010). The 
microarray data for AFSC discussed in this publication have been deposited 
in NCBI’s Gene Expression Omnibus (Ref: GSE 26940) and are accessible 
through the GEO Series accession number GSE26940 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?token=lpebjummoqmqqte&acc=GSE2694
0). The microarray data for TCam-2 cells were previously published.49
Genotyping and RT-PCR sequencing. In silico identification of common 
exonic SNPs in the H19 gene was carried out using the UCSC Genome 
Browser dbSNP (http://genome.ucsc.edu/cgi-bin/hgGateway). Genomic 
DNA was amplified over rs2075745 in exon 1 on H19 (accession no. 
NR_002196) and sequenced to detect heterozygous samples. Total RNA 
was reverse transcribed in parallel with a control omitting reverse tran-
scriptase and cDNA integrity checked using β-ACTIN primers. RT-PCR 
was carried out, products sequenced, and analyzed using the 4Peaks soft-
ware (http://mekentosj.com/).
Analysis of DMD methylation of H19 by bisulphite sequencing. DNA 
from one sample was treated with sodium bisulphite and purified using 
the EZ DNA Methylation-Gold kit (Zymo, Irvine, CA). We amplified the 
bisulphite-treated DNA using primers specific for bisulphite converted 
DNA at the H19 DMD, using Hotstar Taq Polymerase (Qiagen) for 45 
cycles; 3 μl of the amplicon were ligated into TOPO TA vector (Invitrogen) 
as per the manufacturers’ instructions. JM109 chemically competent cells 
were then transformed and 20 white colonies selected and amplified using 
M13 primers for 30 cycles. Amplification of the H19 DMD was verified on 
agarose gel, and each amplicon of appropriate size was sequenced directly. 
Quality control of our bisulphite sequencing data was performed in a stan-
dardized manner using BiQ analyser. Bead on a string diagrams were pro-
duced using BiQ Analyser.
Differentiation into endoderm, ectoderm, and mesoderm lineages
Definitive endoderm. Differentiation was carried out using the Human 
Pluripotent Cell-derived Endoderm Differentiation kit (catalog 
no. SC019; R&D Systems, Minneapolis, MN) over 5 days in Activin 
A-supplemented medium, according to the manufacturer’s instructions. 
Cells were subsequently assessed for expression of the definitive endoderm 
markers SOX17, HNF-3β, CXCR4, and GSC and downregulation of the 
extraembryonic endoderm marker SOX7.
Hepatic. Cells were seeded at a concentration of 5,000 cells/cm2 
on tissue culture plastic plates and coverslips coated with Matrigel 
(BD Biosciences, Franklin Lakes, NJ) and cultured in high glucose 
DMEM supplemented with 1% Penicillin/Streptomycin (Invitrogen), 
2 mmol/l L-Glutamine (Invitrogen) and 10% FBS for 3 days. The 
media were then changed to high glucose DMEM supplemented 
with 15% FBS, 1% Penicillin/Streptomycin, 2 mmol/l L-Glutamine, 
300 μmol/l Monothioglycerol (Sigma-Aldrich), 20 ng/ml Hepatocyte 
Growth Factor (Peprotech), 10 ng/ml Oncostatin M (Peprotech), 10−7 
Dexamethasone (Sigma-Aldrich), 100 ng/ml FGF4 (Peprotech), and 
1X ITS (Insulin, Transferrin, selenium; Sigma-Aldrich). The cells were 
allowed to differentiate for 21 days and then fixed and stored in PBS 
for immunofluorescence. The differentiation media were collected and 
analyzed for the presence of urea secreted by the differentiated cells. Urea 
was subsequently measured using the Urea/Ammonia determination kit 
(R-Biopharm AG, Darmstadt, Germany) according to the manufacturers’ 
instructions. Cells were subsquently assessed for expression of the 
hepatocyte markers ALBUMIN and AFP.
Ectoderm. AFSC were seeded at a concentration of 3,000 cells/ cm2 
on tissue culture plastic plates and coverslips and cultured in DMEM/
F12 (1:1) supplemented with 1% Penicillin/Streptomycin, 2 mmol/l L-
Glutamine, 0.6% glucose (Sigma-Aldrich), 3 mmol/l sodium bicarbonate 
(Sigma-Aldrich), 5 mM HEPES buffer (Sigma-Aldrich), 25 mg/ml insulin 
(Sigma-Aldrich), 100 mg/ml transferrin (Sigma-Aldrich), 20 nmol/l 
progesterone (Sigma-Aldrich), 60 mmol/l putrescine (Sigma-Aldrich), 
30 nmol/l selenium chloride (Sigma-Aldrich), 20 ng/ml EGF (Peprotech), 
10 ng/ml bFGF (Peprotech), and 10 ng/ml LIF (Sigma-Aldrich). Media 
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were changed every 3 days and the cells were allowed to differentiate for 21 
days, before being assessed for expression of NESTIN and VIMENTIN.
Neuronal. AFSC were seeded at a concentration of 5,000 cells/cm2 on 
tissue culture plastic plates and coverslips and cultured in high glucose 
DMEM supplemented with 1% Penicillin/Streptomycin (Invitrogen), 
2 mmol/l L-Glutamine (Invitrogen), and 10% FBS (Biosera, East Sussex, 
UK) for 1 day. The media were then changed to high glucose DMEM 
supplemented with 0.5% FBS, 1% Penicillin/Streptomycin, 2 mmol/l L-
Glutamine, and 0.1% Baicalin (Sigma-Aldrich), freshly made. C17.2 mouse 
neural progenitor cells (gift from Henrik Hagberg and Pierre Gressens) 
were added in a co-culture setting to promote differentiation, using co-
culture membrane inserts (Thermo Scientific Nunc, Loughborough, 
UK). The cells were allowed to differentiate for 5 days and assessed for 
expression of the neuronal markers β-TUBULIN and MAP2 and for the 
NMDA receptor NR1.
Oligodendrocyte. Cells were seeded at a concentration of 5,000 
cells/cm2 on tissue culture plastic plates and coverslips and cultured in 
high glucose DMEM supplemented with 1% Penicillin/Streptomycin 
(Invitrogen), 2 mmol/l L-Glutamine (Invitrogen), 1X N1 supplement 
(Sigma-Aldrich), 1 μg/ml biotin (Sigma-Aldrich), 5 ng/ml bFGF 
(Peprotech), 1 ng/ml PDGF (Peprotech), and 30% B104-conditioned 
media for 1 day. On the second day, CG4 rat oligodendrocyte progenitor 
cells were added in a co-culture setting to promote differentiation, using 
co-culture membrane inserts, and the media were changed every 2 days. 
The cells were allowed to differentiate for 5 days and were then fixed and 
stored in PBS for immunofluorescence. Cells were subsequently assessed 
for expression of the oligodendrocyte markers O2 and NG2.
Mesoderm lineages. Adipogenic, osteogenic, and chondrogenic 
differentiations were performed as previously described.45
Karyotyping. Cells were cultured at subconfluency and processed while 
mitotically active by a cytogenetics service (The Doctors Laboratory, 
London, UK).
Statistical analysis. Statistical analysis was performed using InStat Version 
3.0a statistical software (GraphPad Software, La Jolla, CA). P < 0.05 was 
significant.
suPPleMentArY MAterIAl
Figure S1. Isolation of first trimester AFSC.
Figure S2. Phenotype of first trimester AFSC cultured in Nutristem 
medium.
Figure S3. Positive and negative controls for immunostaining.
Figure S4. Differentiation into mesodermal lineages.
Figure S5. Expression of PGC markers and H19 status of TCam-2 
cells.
Table S1. Results of the tissue expression enrichment analyses per-
formed using the DAVID database. Only significant results (p < 0.05) 
are displayed. “Count” is the number of genes from the input gene list 
that are expressed in the corresponding tissue.
Table S2. List of primers used for RT-PCR and quantitative real-time 
RT-PCR which do not amplify pseudogenes.
Table S3. List of antibodies used for IF and FC.
Table S4. Lists of significantly enriched genes and associated 
 pathways from the signature gene sets of 740 AFSC-specific genes 
and 7905 genes overlapping between AFSC and hESC and 1748 
hESC-specific genes as given by the DAVID database.
Video S1. Movie showing the beating of AFSC cells upon spontane-
ous differentiation.
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